n=16. This isn't even worthy of classifying as a Phase I trial. Efficacy studies generally _start_ at n=100. Drawing any conclusions on efficacy from this kind

n=16. This isn't even worthy of classifying as a Phase I trial. Efficacy studies generally _start_ at n=100. Drawing any conclusions on efficacy from this kind of sample size is simply unscientific.